Summary Background The European Organisation for Research and Treatment of Cancer
(EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients …

Background Patients with stage IIB or IIC melanoma who undergo surgery alone are at a
substantial risk for disease recurrence. Adjuvant pembrolizumab significantly improved …

PURPOSE We conducted the phase III double-blind European Organisation for Research
and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab …

Background Pembrolizumab prolongs progression-free and overall survival among patients
with advanced melanoma and recurrence-free survival in resected stage III disease …

Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to
prolong progression-free and overall survival among patients with advanced melanoma. We …

Background In the previously reported primary analyses of this phase 3 trial, 12 months of
adjuvant pembrolizumab resulted in significantly longer recurrence-and distant metastasis …

Summary Background The European Organisation for Research and Treatment of Cancer
(EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III …

Patients with high-risk stage II melanoma are at significant risk for recurrence after surgical
resection. Adjuvant treatment options to lower the risk for distant metastases are limited …

Background The IMMUNED trial previously showed significant improvements in recurrence-
free survival for adjuvant nivolumab plus ipilimumab as well as for adjuvant nivolumab alone …

Background Whether pembrolizumab given both before surgery (neoadjuvant therapy) and
after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant …